Biography

Tawanda Gumbo, M.D., was born in Zimbabwe, and attended the University of Zimbabwe Medical School. From 1993 to 1996 he was an intern and resident in Internal Medicine/International Health Tract at Case Western Reserve University at MetroHealth Medical Center in Cleveland, Ohio, and from 1996-1999 he was a fellow in Infectious Diseases at the Cleveland Clinic Foundation in Cleveland, Ohio.

In 2001 he joined the Albany Medical College and the Ordway Research Institute in Albany, New York, where he worked on establishing the mouse model of disseminated Candida glabrata and the hollow fiber model of tuberculosis in 2002. He was the inaugural Director of Transplant Infectious Diseases for the newly established transplant surgery program, and the Infectious Diseases member of Center for Donation and Transplant (CDT), a UNOS organ procurement organization for New York, Vermont, and Western Massachusetts.

In 2006 he moved to UT Southwestern Medical Center. The Gumbo Laboratory has elucidated the role of efflux pumps in survival of Mycobacterium tuberculosis and examined molecules that could exploit these to enhance antituberculosis therapy. Work has also included integrating pharmacogenomics into clinical trial simulations for antituberculosis drugs with multimodal systemic elimination, establishment of a mathematical model for the relationship between antimicrobial drug exposure and resistance emergence, the establishment of new susceptibility breakpoints of first-line antituberculosis drugs, and recently a series of hollow fiber model of tuberculosis and computer-aided clinical trial simulations as well as clinical data that have questioned the role of adherence in therapy failure and proposed the pharmacokinetic variability hypothesis for therapy failure and acquired drug resistance. These findings were then confirmed in a series of clinical studies conducted jointly with research partners at the University of Cape Town. 

In 2007 he received the NIH Director’s New Innovator Award to focus on efflux pump inhibition to accelerate therapy and reduce duration of antituberculosis therapy. In 2009 he was a Mellon Visiting Scholar at the University of Cape Town in South Africa. In 2013 the hollow fiber model of tuberculosis was presented before the FDA, and in 2014 presented to the European Medicines Agency for qualification as a drug development tool by CPTR. 

He is a contributor for two chapters in the 12th edition of the pre-eminent pharmacology text "Goodman and Gilman’s The Pharmacological Basis of Therapeutics" namely, "Principles of Chemotherapy of Infectious Diseases" and "Chemotherapy of Tuberculosis, Mycobacterium avium Complex, Leprosy." Dr. Gumbo has also published a poetry book, "Songs for flame lily" (2005), that is arranged based on courtship stages of traditional Bantu society.

He joined UT Southwestern's Office of Global Health in 2011.

Education

Medical School University of Zimbabwe (1991)
Internship/Residency Case Western Reserve University at Metro Health (1996), Internal Medicine
Other Post Graduate Training Cleveland Clinic Foundation (1999), Infectious Disease

Research Interest

  • Advanced pharmacometrics, antimicrobial pharmacokinetic-pharmacodynamics and pharmacogenetics
  • Application of fractal geometry and chaos theory to quantitative and systems pharmacology
  • Computer aided clinical trial simulations
  • Development of novel efflux pump Inhibitors to enhance antibiotic efficacy
  • Individualized Bayesian feedback dose optimization
  • Mathematical model development for the relationship between mycobacterial cells and drug concentration
  • Systems Pharmacology and mathematical scaling studies for M. tuberculosis, M. avium complex, and M. kansasii

Publications

Featured Publications LegendFeatured Publications

The pyrazinamide susceptibility breakpoint above which combination therapy fails.
Gumbo T, Chigutsa E, Pasipanodya J, Visser M, van Helden PD, Sirgel FA, McIlleron H J. Antimicrob. Chemother. 2014 May
Integrating drug concentrations and minimum inhibitory concentrations with Bayesian-dose optimisation for multidrug-resistant tuberculosis.
Srivastava S, Gumbo T Eur. Respir. J. 2014 Jan 43 1 312-3
Therapy duration and long-term outcomes in extra-pulmonary tuberculosis.
Pusch T, Pasipanodya JG, Hall RG, Gumbo T BMC Infect. Dis. 2014 14 115

Books

Featured Books Legend Featured Books

Honors & Awards

  • Mellon Visiting Scholar
    University of Cape Town (2009)
  • NIH Director’s New Pioneer Innovator Award
    National Institutes of Health (2007)
  • Certificate of Distinction
    Australian Mathematics Competition for the Westpac Awards, Senior Division (1986)

Professional Associations/Affiliations

  • American Association for the Advancement of Science
  • American Society for Microbiology
  • Infectious Diseases Society of America
  • International Society of Anti-Infective Pharmacology